CHEST Pulmonary Vascular and Cardiovascular

#CHESTPulmCardio | @accpchest
Co-chairs: @FSotoMD, @sandeepsahayMD, @RaedDweikMD

[Francisco Soto, MD, MS, MBA @FSotoMD]

You walk into the ICU 🏥.

100 mg IV Lasix about to be 💉.

PA 51/22 (mean 32)
Wedge 30

Do you 🛑✋ it?

7 practical ✅ I use to whether I can trust the wedge 👇🏻

[CHEST Pulmonary Vascular and Cardiovascular @CHESTPulmCardio]

Sotatercept study in Combined Pre/Post Capillary PH (CADENCE)

Encouraging PVR reduction results 👇🏻

[Francisco Soto, MD, MS, MBA @FSotoMD]

1/6

Sotatercept in Combined Pre/Post Capillary PH (CpcPH): CADENCE (Gomberg-Circulation 2026)

A🧵 (8 min read)

But first.

🔹Pulm vasodilators NOT approved for PH with ⬆️ left ♥️ pressures (wedge >15; Group 2 PH). Individualized approach recommended. Humbert (2022)

🔹In group 2 PH (PH LHD), pulmonary vasodilation risks “flooding” the left ♥️ and lungs, d/t ⬆️ wedge and impaired LA relaxation

🔹Studies: no benefit or ⬆️ risks (table 👇🏻)

[CHEST Pulmonary Vascular and Cardiovascular @CHESTPulmCardio]

And the mandatory selfies and group pictures

[CHEST Pulmonary Vascular and Cardiovascular @CHESTPulmCardio]

Great attendance and meeting of the Pulmonary Vascular and Cardiovascular Network this morning.

Dr Shlobin led the session and updated the audience on the superb lectures and activities put together by the network for #chest2025 @accpchest

[CHEST Pulmonary Vascular and Cardiovascular @CHESTPulmCardio]

Dr Farbod Rahaghi was the network’s invited speaker.

Great lecture on “What is new in AI and pulmonary vascular disease”

[Francisco Soto, MD, MS, MBA @FSotoMD]

Colleague: “I wish I’d find a lecture explaining hemodynamics and cardiopulmonary interaction in an easier way…”

Me: “Wait, aren’t you going to Chicago’s #CHEST2025?

Colleague: “I am, but I don’t want generic concepts. I want to learn how the experts do it.”

Me: Say no more!

We put together an amazing session just for you!

Join us:
👇
🎯 Session Title: "Pulmonary Circulation Advanced Interrogation — How I Do It"

💡 Go beyond routine caths: unmask hidden shunts, interpret difficult wedge pressures, and master fluid/exercise challenges like the experts do.

📅 Tuesday, Oct 21 — 8-9 AM

📍 South Building 503 — Session ID 1067

@accpchest @ChestPulmCardio @ChestCritCare

[Roberto J. Bernardo, MD, MS, ATSF 🇵🇪🇺🇸 @rjbernardoMD]

#ATS2025

https://t.co/x7KkxVI2U4

[CHEST Pulmonary Vascular and Cardiovascular @CHESTPulmCardio]

Amazing @PHAssociation Conference, Indianapolis August 2024

Saturday Fashion Show, with the stars of the conference ❤️❤️

Our patients, the real motivation for what we do in @CHESTPulmCardio

[CHEST @accpchest]

The Pulmonary Vascular Disease Section shares findings from the largest reported study on real-world right heart catheterization practices by pulmonary hypertension physicians: https://t.co/4Y4cVyr9Dr

[The Pulmonary Vascular Research Institute @PVRI]

Full house for the Community Call today! We'll be here for the next 40 minutes discussing the latest in PH: https://t.co/JHvnzgmHwR #PulmonaryHypertension

[Francisco Soto, MD, MS, MBA @FSotoMD]

The Pulm Vasc and Cardiovasc Dz network is very proud @CHESTPulmCardio

Our network’s chair, Dr Elwing @ElwingJean was awarded the Distinguished Scientist Honor Lecture in Cardiopulmonary Physiology at #CHEST2023 @accpchest

A great researcher and an amazing and generous mentor

[Jean-Luc Vachiery 🫀 @jeanlucvachiery]

@OSitbon @ErsPvd And now STELLAR #Marius #Hoeper on the sotatercept story #ERSCongress #ERS2023 @ErsPvd @AlbertaPHdoc

[Jason Weatherald MD @AlbertaPHdoc]

What’s in the pipeline for disease modification approaches in #PAH? Targeting epigenetic modification may a path forward in the future. Fascinating talk from @PullamsettiL
#ERS2023 #ERSCongress
@ErsPvd @sbonnet2

[Jason Weatherald MD @AlbertaPHdoc]

Are our existing #PAH therapies disease modifying? Maybe, probably. Masterful talk by my friend and mentor @OSitbon
#ERS2023 #ERSCongress

[Jason Weatherald MD @AlbertaPHdoc]

Dr Marius Hoeper provides an update on #sotatercept. Is it a disease modifying agent?
Where will it fit in the treatment algorithm?
#ERS2023 #ERSCongress @ErsPvd @EuroRespSoc

[James D Chalmers @ProfJDChalmers]

Looking forward to meeting all of the @EuroRespSoc Early career members later today to talk about manuscript writing and publishing
Great to see the focus at #ers2023 on opportunities and skills for early career members @EarlyCareerERS

[Jason Weatherald MD @AlbertaPHdoc]

Interesting #seralutinib imaging substudy of #TORREY phase 2 trial, showing improvement in BV5A/BV10A. Suggests reverse remodeling? Correlated with improvement in stroke volume and PCa. #ERSCongress #ERS2023 @ErsPvd
#PulmonaryHypertension